면역관문억제제 시장 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Immune Checkpoint Inhibitors Market reached USD 47.4 billion in 2023 and is projected to register a CAGR of 16.7% from 2024 to 2032. This growth is driven by the rising global cancer prevalence and demand for advanced, personalized therapies. Immune checkpoint inhibitors enhance the immune system's ability to target cancer cells, showing effectiveness against melanoma, lung cancer, and renal cell carcinoma. Extensive clinical trials, favorable regulatory approvals, and integration into treatment protocols support market expansion. Increased investments in oncology research and a strong pipeline of new inhibitors sustain market growth. For instance, in July 2021, the Rankin government invested USD 18 million in cancer therapies, including immune checkpoint inhibitors. In 2023, the Cancer Research Institute allocated USD 28 million for cancer immunotherapy research. Such support from governmental and organizational entities is crucial for market growth.

The overall immune checkpoint inhibitors industry is classified based on the type, application, end-use, and region.

Immune checkpoint inhibitors block proteins known as checkpoints, enhancing immune cells' ability to attack cancer cells. The market is categorized by type: PD-L1, CTLA-4, PD-1, and others. The PD-1 segment dominated in 2023 with USD 34.7 billion. PD-1 inhibitors, like nivolumab and pembrolizumab, show impressive efficacy across various cancers, including non-small cell lung cancer, melanoma, and renal cell carcinoma. Robust clinical outcomes and growing adoption within oncology practices reinforce the leading market position of PD-1 inhibitors.

The market is segmented by application into melanoma, breast cancer, lung cancer, bladder cancer, Hodgkin lymphoma, cervical cancer, colorectal cancer, and others. In 2023, lung cancer led with a 25.1% share. Lung cancer's significant burden and the proven efficacy of these therapies enhance patient outcomes. In 2023, the U.S. saw 238,340 new lung cancer diagnoses, with approximately 127,070 fatalities. Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have shown success in treating non-small cell lung cancer (NSCLC). Ongoing research and clinical trials are broadening the application of these inhibitors across various lung cancer stages.

In 2023, North America held a USD 22.9 billion share of the market, with a projected CAGR of 16.8% from 2024 to 2032. The presence of leading pharmaceutical companies and a favorable regulatory landscape bolster the North American market. The American Cancer Society estimates around 2,170,450 new cancer cases in the U.S. and Canada in 2024, highlighting the demand for advanced cancer therapies. Additionally, increasing government funding for cancer research and treatment is further driving the market's growth in the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising cancer incidence across the world
    • 3.2.1.2 Ongoing research and development in immunotherapy
    • 3.2.1.3 Favorable regulatory environment
    • 3.2.1.4 Increasing investments and partnerships
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Adverse side effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 PD-1
• 5.3 PD-L1
• 5.4 CTLA-4
• 5.5 Other types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Lung cancer
• 6.3 Breast cancer
• 6.4 Bladder cancer
• 6.5 Melanoma
• 6.6 Cervical cancer
• 6.7 Hodgkin lymphoma
• 6.8 Colorectal cancer
• 6.9 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Cancer centers
• 7.4 Academic and research institutes

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AstraZeneca PLC
• 9.2 BeiGene, Ltd.
• 9.3 Bristol-Myers Squibb Company
• 9.4 Eli Lilly and Company
• 9.5 F. Hoffmann-La Roche Ltd.
• 9.6 GlaxoSmithKline plc
• 9.7 Incyte Corporation
• 9.8 Immutep Limited
• 9.9 Merck and Co., Inc.
• 9.10 Regeneron Pharmaceuticals, Inc.
• 9.11 Sanofi
• 9.12 Shanghai Junshi Biosciences Co., Ltd.